Aspira Women's Health Files 8-K on Financials
Ticker: AWHL · Form: 8-K · Filed: Mar 28, 2024 · CIK: 926617
| Field | Detail |
|---|---|
| Company | Aspira Women'S Health INC. (AWHL) |
| Form Type | 8-K |
| Filed Date | Mar 28, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, company-history
TL;DR
Aspira Women's Health dropped an 8-K on March 28th detailing their financial condition. Check it out.
AI Summary
Aspira Women's Health Inc. filed an 8-K on March 28, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 12117 Bee Caves Road, Building III, Suite 100, Austin, Texas 78738. The company was formerly known as Vermillion, Inc., Ciphergen Biosystems Inc., and Abiotic Systems.
Why It Matters
This filing provides crucial updates on Aspira Women's Health Inc.'s financial performance and condition, which is essential for investors to assess the company's stability and future prospects.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for financial reporting and does not appear to contain any immediate negative news or significant changes.
Key Players & Entities
- Aspira Women's Health Inc. (company) — Registrant
- March 28, 2024 (date) — Date of Report
- 12117 Bee Caves Road, Building III, Suite 100, Austin, Texas 78738 (location) — Principal Executive Offices
- Vermillion, Inc. (company) — Former Company Name
- Ciphergen Biosystems Inc (company) — Former Company Name
- Abiotic Systems (company) — Former Company Name
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Aspira Women's Health Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on March 28, 2024.
What is the company's principal executive office address?
The company's principal executive office is located at 12117 Bee Caves Road, Building III, Suite 100, Austin, Texas 78738.
What were some of Aspira Women's Health Inc.'s former company names?
Aspira Women's Health Inc. was formerly known as Vermillion, Inc., Ciphergen Biosystems Inc, and Abiotic Systems.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This report is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
Filing Stats: 513 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-03-28 16:50:32
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share AWH Nasdaq Capital Market
Filing Documents
- awh-20240328x8k.htm (8-K) — 72KB
- awh-20240328xex99_1.htm (EX-99.1) — 244KB
- awh-20240328xex99_1g001.jpg (GRAPHIC) — 5KB
- 0000926617-24-000009.txt ( ) — 459KB
- awh-20240328.xsd (EX-101.SCH) — 2KB
- awh-20240328_lab.xml (EX-101.LAB) — 15KB
- awh-20240328_pre.xml (EX-101.PRE) — 11KB
- awh-20240328x8k_htm.xml (XML) — 5KB
02 Results of Operations and Financial Conditions
Item 2.02 Results of Operations and Financial Conditions. On March 28, 2024, Aspira Women's Health Inc. (the "Company") issued a press release reporting financial results for the three and twelve months ended December 31, 2023. A copy of the Company's press release is attached hereto as Exhibit 99.1. The information provided in this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section. Such information shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by Aspira Women's Health on March 28, 2024 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ASPIRA WOMEN'S HEALTH INC. Date: March 28, 2024 By: /s/ Torsten Hombeck Torsten Hombeck Chief Financial Officer